Drug Trial Radar · NCT06138132
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyverna Therapeutics
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
Conditions
- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
Interventions
KYV-101 anti-CD19 CAR-T cell therapyBiological
KYV-101 anti-CD19 CAR-T cell therapy
Standard lymphodepletion regimenDrug
Standard lymphodepletion regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of dose limiting toxicities at each dose levelTime frame: Up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford Multiple Sclerosis Center
Palo Alto, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.